An FDA advisory panel recommended updating COVID-19 vaccines for the 2026-2027 season on May 28, 2026. The committee voted 8-1, with one abstention, to target the currently dominant XFG variant.
This decision provides a production roadmap for the upcoming fall immunization campaign. Moderna, Pfizer-BioNTech, and Sanofi confirmed they are prepared to supply XFG-targeted shots in a timely manner.
FDA staff raised concerns regarding limited surveillance data for currently circulating viruses during the recommendation process.